Our Strategy

We partner with entrepreneurs to create companies that have a significant impact on patients’ lives. Participating at all stages of development and across all sectors, we take a broad strategic approach to investing in life sciences.

Typical Investments

Investment size$15-$30m in total per company
OwnershipMajority or minority
GeographyPrimarily US and Europe
Holding period3-8 years
SectorsBiotherapeutics, small molecules, nucleic acid therapeutics, vaccines, specialty pharma, technologies, medical devices, diagnostics, instrumentation

BROAD STRATEGIC APPROACH

Within the life sciences market we participate in a wide range of opportunities spanning therapeutics, medical devices, diagnostics, instrumentation and software. We invest in seed stage projects, technology platforms, preclinical and clinical assets as well as approved and marketed products. Supporting private and public companies, we aim to partner with the most innovative entrepreneurs to address significant unmet needs in healthcare.

Discover the Strategies

Covering programmes and companies at many different stages of development, our diverse strategies provide us with unusually broad insights into the key factors for success in biotechnology.

"I was impressed by Abingworth’s thoughtful, candid and rigorous diligence process, and their interest in building a relationship with management before they became investors. That approach created mutual understanding and trust, and laid the foundation for a highly productive partnership."

Timothy Noyes, President and CEO of Proteon Therapeutics

"Abingworth not only devised and executed a thorough diligence process, but as our lead Series A investor, galvanized a strong long-term investor syndicate. Through their expansive network, they also helped us secure the site of our new corporate headquarters in an intensely competitive real estate market."

Grant Pickering, President and CEO of SutroVax

"I feel fortunate to have Abingworth as an investor in Wilson Therapeutics. Their in-depth knowledge of drug development in combination with being very well connected in the life science industry adds great value to our company."

Jonas Hansson, CEO of Wilson Therapeutics

"Abingworth is an excellent investor for GammaDelta Therapeutics. Using strong scientific expertise and astute business sense they drove the seed investment with King’s College and the Crick institute and then our highly productive collaboration with Takeda. High quality science and ethical behaviour form the foundation of day-by-day activities at Abingworth and it is extremely reassuring to have such partners."

Paolo Paoletti, CEO of GammaDelta Therapeutics

"Abingworth is a very supportive investor. Their extensive network, deep sector knowledge, willingness to engage at different levels, from strategy discussions to finding key advisors and talent, has been very important for a growing, entrepreneurial company like Verona Pharma."

Jan-Anders Karlsson, CEO